Abstract
Although colorectal cancer (CRC) is the second leading cause of death in developed countries, its diagnostics tests for early disease stages are suboptimal. We have performed a combination of UHPLC-MS metabolomics and 16S microbiome analyses in 224 feces samples in order to identify early biomarkers for both advanced adenomas (AD) and CRC. We report differences in fecal levels of cholesteryl esters and sphingolipids in CRC. We identified Fusobacterium, Parvimonas and Staphylococcus to be increased in CRC patients and Lachnospiraceae family to be reduced. We finally described Adlercreutzia to be more abundant in AD patients’ feces. Integration of metabolomics and microbiome data revealed tight interactions between bacteria and host and performed better than FOB test for CRC diagnosis. This study identifies potential early biomarkers that outperform current diagnostic tools and frame them into the established gut microbiota role in CRC pathogenesis. Funding Statement: Centro de Investigacion Biomedica en Red en el Area tematica de Enfermedades Hepaticas y Digestivas (CIBERehd) is funded by the Institute of Health Carlos III. This work has been supported by Instituto de Salud Carlos III (PI12/01604 to JMF-P, PI11/0094 and PI17/00837 to JC), BG2016-INVESTIGACION COLABORATIVA EN MEDICINA DE PRECISION Y BIOMARCADORES (Ref. KK-2016/00026) funded by Basque Government and from Programa Interreg V-A Espana-Portugal 2014-2020 (POCTEP), 0181_NANOEATERS_1_EP to JC. All of them co-financed by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: This study was approved by the Clinical Research Ethics Committee of Galicia (Code 2011/038).
Highlights
Colorectal cancer (CRC) represents almost 10% of global cancer incidence [1], being the second leading cause of death in developed countries [2]
Male individuals presented with major prevalence of both AD and colorectal cancer (CRC) when compared to healthy group (62.23%, 59.60% vs. 44.74%) and they were older that control group (67.99, 70.16 vs. 64.62 years old respectively)
Both group of patients presented with higher presence of fecal occult blood (FOB) compared to controls, as well as CEA
Summary
Colorectal cancer (CRC) represents almost 10% of global cancer incidence [1], being the second leading cause of death in developed countries [2]. There is a need for new molecular parameters that are able to distinguish between CRC types for a better treatment outcome [1] In this context, metabolomics of feces samples have provided new non-invasive, accurate and predictive biomarkers for CRC, as our group and other authors have suggested [7,8,9]. Among the factors that influence these metabolisms, and may be related to CRC development and progression, the microbiota has been recurrently pointed to be one of them and suggested the bacterial driver-passenger hypothesis for CRC initiation and progression [15,16] This hypothesis is highly supported by the fact that germ-free mice models susceptible to CRC have fewer tumors that non-germ-free mice [17,18,19]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
